Ureas (i.e., N-c(=o)-n) Patents (Class 514/588)
  • Patent number: 10000390
    Abstract: A method of synthesizing silica nanoparticles. The method includes hydrolyzing a silica precursor to form a plurality of monomers, each monomer of the plurality comprising a microwave reactive silicon species. The plurality of monomers is irradiated by an energy source configured to generate microwave frequency energy. Irradiation cases the plurality of monomers polymerize into a silica nanoparticle.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: June 19, 2018
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Jeffery Ray Owens, Derek Lovingood
  • Patent number: 9926337
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: March 27, 2018
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Claudio Giuliano, Silvina Garcia Rubio, Antoine Daina, Angelo Guainazzi, Claudio Pietra
  • Patent number: 9682144
    Abstract: The present invention relates to a composition or kit of parts comprising an inhibitor of IRS-1 and an inhibitor of the VEGF pathway and to the use thereof for treating an angiogenic disease.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: June 20, 2017
    Assignee: GENE SIGNAL INTERNATIONAL, SA
    Inventors: Eric Thorin, Salman Al-Mahmood, Sylvie Colin, Antoine Ferry, Eric Viaud
  • Patent number: 9420797
    Abstract: An aqueous biocidal composition comprising a mixture of hydrochloric acid (HCl), urea, and sodium hypochlorite (NaOCl) at acidic pH, a method for manufacturing the composition and a biocidal technology for treating industrial water.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: August 23, 2016
    Assignee: Bromine Compounds Ltd.
    Inventors: Shlomo Antebi, David Feldman, Chen Zolkov
  • Publication number: 20150148422
    Abstract: A method for using urea sulfate as an anti-microbial agent, anti-mold agent, anti-fungal agent, and pH adjusting compound with the benefit of adding nitrogen and sulfur to the food supply. Urea sulfate provides a fundamental contribution to feed hygiene, as it suppresses the growth of mold and thus restricts the potential effect of mycotoxins. Consequently, feed safety is improved by adding this compound.
    Type: Application
    Filed: June 28, 2013
    Publication date: May 28, 2015
    Applicant: JSK Capital, LLC
    Inventors: Gerald Stanley Rose, SR., Bobby Joel Ivey, Kevin Aaron Rose
  • Publication number: 20150132405
    Abstract: The present invention provides synergistic combinations of monochlorourea with other biocides for controlling microbial growth in aqueous systems. It also provides synergistic combinations of dimethyl monochlorourea with other biocides for controlling growth in aqueous systems. The synergistic combinations of monochlorourea and dimethyl monochlorourea with other biocides allows for the reduced use of total biocides to provide control of microbial growth in aqueous systems.
    Type: Application
    Filed: March 14, 2014
    Publication date: May 14, 2015
    Applicant: HERCULES INCORPORATED
    Inventor: John S Chapman
  • Publication number: 20150111911
    Abstract: Discovery of a new Bax isoform, Bax?2, in cancer cell lines and primary tumors is described. The Bax?2 isoform resulted from combination of Bax microsatellite mutation and alternative splicing Bax exon 2. It is also discovered that Bax?2 renders cancer cells sensitive to certain chemotherapeutic drugs that target caspase 8. Also provided are methods for treating colorectal cancer by administering to a colorectal cancer patient a chemotherapeutic agent that is capable of activating caspase 8, wherein the patient contains a cancer cell that expresses a Bax?2 protein (SEQ ID NO. 2).
    Type: Application
    Filed: August 14, 2014
    Publication date: April 23, 2015
    Applicant: Mumetel, LLC
    Inventors: Jialing Xiang, Li Ma
  • Publication number: 20150110713
    Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Inventors: Anthony Manganaro, Karen Rockwell
  • Publication number: 20150051288
    Abstract: Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder.
    Type: Application
    Filed: October 10, 2014
    Publication date: February 19, 2015
    Inventors: Paul Talalay, Andrew W. Zimmerman, Kirby D. Smith
  • Patent number: 8952067
    Abstract: Topical dermatological preparations including one or more lipodissolving, lipolytic, or adipocyte-disrupting substances for treatment of localized adiposity can include carbamide peroxide and a terpene such as d-limonene. In some embodiments, the preparations can include carbamide peroxide as a first component and, as a second component, at least one peppermint oil terpene, peppermint oil, or a compound isolated or derived from peppermint oil.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: February 10, 2015
    Assignee: Atheronova Operations, Inc.
    Inventors: Boris Ratiner, Giorgio Zadini
  • Publication number: 20150024053
    Abstract: A topical wound treatment composition comprises a hydrogen peroxide generator; alkaline powder; not more than 5 percent by weight of water; additional topical active agent if desired, and emollient (preferably hygroscopic emollient) to balance. When topically applied to a wound and water from the surrounding environment diffuses into the composition, the hydrogen peroxide generator and/or the alkaline compound diffuse into one another, causing a chemical reaction that generates treatment-effective amounts of oxygen to occur. The oxygen can then diffuse out of the composition and aid in wound treatment or healing.
    Type: Application
    Filed: March 1, 2013
    Publication date: January 22, 2015
    Inventors: Benjamin S. Harrison, Steve J. Hodges
  • Patent number: 8921391
    Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: December 30, 2014
    Assignee: RaQualia Pharma Inc.
    Inventors: Yukinori Take, Shinichi Koizumi, Takako Okumura, Kazuhiko Nonomura
  • Patent number: 8906421
    Abstract: The present invention provides an aqueous composition and its use for dissolving blood clots in vivo or in clinical or research samples in vitro, said composition comprising at least one chaotropic agent, at least one chelating agent that complexes iron if the chaotropic agent does not complex iron and at least one surface-active emulsifier, the composition being buffered near pH 7.4. The process of dissolving the clot with the aqueous composition is advantageous because it is simple, inexpensive, rapid and can be applied in a variety of contexts, including basic research and clinical situations.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: December 9, 2014
    Assignee: MED-Genesis, LLC
    Inventors: John S. Fisher, Fred Ahari, Christopher Jon Perry, Lucjan J. J. Hronowski
  • Publication number: 20140350106
    Abstract: Compositions and methods for urea silicone gels for treating skin conditions that may benefit from barrier protection and from urea silicone gel ability to return water balance to the skin are disclosed. Skin conditions that may be treated with urea silicone gel may be excessive dryness, insect bites, keloids and scars, among others. Disclosed urea silicone gel may include micronized urea USP, an anhydrous silicone base, and a PEG ointment base, among other ingredients. Anhydrous silicone base may include Amazonian oils such as pracaxi oil and seje oil, which are rich in oleic, linolenic, linoleic acids, and sterols, particularly beta-sitosterol and stigmasterol that may increase skin permeability to urea. PEG ointment base may be water-washable and includes meadowsweet extract. Additionally, PEG urea silicone gel may provide occlusion, and may maintain a moist environment within the skin condition which allows optimal healing. Pain also may be decreased by maintaining a moist environment.
    Type: Application
    Filed: May 22, 2013
    Publication date: November 27, 2014
    Applicant: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
    Inventor: Fabiana Campanati Banov
  • Patent number: 8889906
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: November 18, 2014
    Assignee: Roche Palo Alto LLC
    Inventors: Robert Greenhouse, Ralph New Harris, III, Saul Jaime-Figueroa, James M. Kress, David Bruce Repke, Russell Stephen Stabler
  • Patent number: 8883131
    Abstract: A synergistic composition, or the use of that composition in the manufacture of a medicament, or a method of treatment including the use of that composition, for the treatment of hair loss and baldness, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal embodiment the composition consists, in the form of a lotion: 1600-2400 IU/mL Vitamin A Palmitate, 0.64%-0.96% Thiamine Hydrochloride, 0.64%-0.96% Pyridoxine Hydrochloride, 4.8%-7.2% Niacinamide, 2.85%-5.2% D-Panthenol, 1.6%-2.4% L-Arginine, 3.6%-4.4% Methyl Sulphonyl Methane (MSM), 0.08%-0.12% Ginger Oil, 0.08%-0.12% Cinnamon Oil, 0.0996%-0.1494% Oleoresin Capsicum, 1.3%-1.95% Magnesium, 2.4%-3.6% Zinc, 0.192%-0.288% Manganese, 2.6%-3.9% Urea, 2.4%-3.6% Sodium Glycerophosphate, 4.8%-7.2% L-Lysine HCl, plus Preservatives, Co-solvent (Propylene Glycol), Fragrances, Anti-Oxidant, Cooling agent (Menthol), Emulsifier, and Vehicle (Purified water).
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: November 11, 2014
    Inventors: Robert Peter Taylor, Kartar Singh Lalvani, Ajit Lalvani
  • Patent number: 8877773
    Abstract: Methods and compositions that down regulate the activity of orexins to treat panic disorder and panic-like responses associated with hypercapnic conditions are disclosed.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: November 4, 2014
    Inventors: Anantha Shekhar, Philip L. Johnson
  • Patent number: 8877968
    Abstract: Melanocortin receptor modulators, processes for preparing them and use thereof in human medicine and cosmetics are described. Melanocortin receptor modulators corresponding to formula (I): compositions containing them, processes for their preparation and their use in pharmaceutical or cosmetic compositions are also described.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: November 4, 2014
    Assignee: Galderma Research & Development
    Inventors: Claire Bouix-Peter, Itaru Suzuki, Isabelle Pelisson, Pascal Collette, Samuel Tabet, Guillaume Lafitte
  • Patent number: 8871812
    Abstract: The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: October 28, 2014
    Inventors: Robert S. Kauffman, Cyril Jean Camille Titeux, Ramon Polo, Rudolf Peter Gerhard Van Heeswijk, Maria Gloria Beumont, Gaston Rafael Picchio
  • Patent number: 8865770
    Abstract: Disclosed are methods of maintaining fertility or treating retained placenta, reproductive tract infection, or reproductive tract inflammation in an animal by administering carbamide peroxide to the reproductive tract of the animal. The carbamide peroxide administration removes placental remains on the uterine wall, protects against or treats reproductive tract infection, and protects against or treats reproductive tract inflammation such as metritis, and thereby maintains fertility in the animal.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: October 21, 2014
    Assignee: Vets Plus, Inc.
    Inventors: Daniel J. DuBourdieu, Raj Lall
  • Publication number: 20140288182
    Abstract: The invention relates to the field of medicament use, in particular to the clinical use of carbamide peroxide injection series for virus inactivation in the treatment of blood vessel plaque, leukemia, AIDS and hepatitis, etc. The invention utilizes the affinity of photosensitizers to blood vessel plaque focus, leukemia cells, tumor, and/or virus, which is several times higher than that to normal tissues, so as to destroy focus cells or virus by generating sufficient singlet oxygen (1O2) under the effect of a method using laser, X-ray, ultrasound and medicament, etc., while in condition of using carbamide peroxide injection series. The effects for treating the above diseases are achieved efficiently without serious side effects to the normal human tissues and organs.
    Type: Application
    Filed: February 19, 2014
    Publication date: September 25, 2014
    Applicant: Wuxi Zhaozhen Radiation Technology Co., Ltd.
    Inventors: Qiyin Sun, Keke Sun
  • Patent number: 8822496
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin and particular regimens for administering this combination. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: September 2, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carla Haefner, Gerhard Steinmann, Jerry O. Stern, Chan-Loi Yong
  • Patent number: 8815259
    Abstract: The invention describes nanotextured super hydrophobic coatings that contain active agents which can elute from the coating over a period of time.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: August 26, 2014
    Assignee: Innovative Surface Technologies, Inc.
    Inventors: Kristin S. Taton, Patrick E. Guire, Laurie R. Lawin, Jie Wen
  • Patent number: 8815951
    Abstract: The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R1 and R3 is each independently C1-C20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: August 26, 2014
    Assignee: The Regents of the University of California
    Inventors: Bruce D Hammock, Jiang Zheng, Christophe Morisseau, Kazuhiko Motoba, Mehran F. Moghaddam, Babak Borhan, David F. Grant, Jessica Greene, Marlene F. Sisemore, James Sanborn
  • Patent number: 8785419
    Abstract: Method of identifying compounds that modulate intermolecular interactions between a target protein and a modifier are disclosed. Pharmaceutical composition comprising compounds that inhibit intermolecular interactions between a target protein and a modifier are disclosed. Methods of treating individual suffering from inflammatory conditions, undesirable immune responses, immunological conditions and bacterial infections are disclosed.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: July 22, 2014
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Ramachandran Murali, Mark I. Greene
  • Publication number: 20140186278
    Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficulty soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.
    Type: Application
    Filed: September 19, 2013
    Publication date: July 3, 2014
    Inventor: Patrick Franke
  • Patent number: 8741265
    Abstract: The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: June 3, 2014
    Assignee: Foamix Ltd.
    Inventors: Dov Tamarkin, Doron Friedman, Meir Eini
  • Patent number: 8728504
    Abstract: A process for solubilizing hydrophobic active ingredients in aqueous medium, which comprises using, as an assistant, at least one hyperbranched polymer (A) which is obtainable by reacting at least one hyperbranched polymeric compound having at least one primary or secondary amino group per molecule (a), selected from (a1) hyperbranched polyamides and (a2) hyperbranched polyureas, with (b) at least one mono-, di- or oligosaccharide.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: May 20, 2014
    Assignee: BASF SE
    Inventors: Bernd Bruchmann, Holger Türk, Daniel Schönfelder, Monika Haberecht, Dietmar Appelhans, Victor Boyko
  • Patent number: 8716320
    Abstract: The present invention provides novel heterocyclic urea compounds having useful antibacterial activity, pharmaceutical compositions comprising one or more of these compounds, methods of making the same, and methods of using the same.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: May 6, 2014
    Assignee: Replidyne, Inc.
    Inventors: Joseph Guiles, Thale Jarvis, Sarah Strong, Xicheng Sun
  • Patent number: 8691874
    Abstract: Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: April 8, 2014
    Assignee: Kato Pharmaceuticals, Inc.
    Inventors: Vicken H. Karageozian, David Castillejos, John Park
  • Publication number: 20140079804
    Abstract: This invention relates to the field of topical treatments for infections such as nail infections, particularly fungal infections of the nail commonly referred to as onychomycosis. Particularly, the invention relates to novel compositions containing peroxide for the treatment of such nail infections and other infections.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 20, 2014
    Applicant: Thompson Cooper Laboratories, LLC
    Inventors: Eugene R. Cooper, Evan R. Thompson, Elliot R. Thompson
  • Patent number: 8669289
    Abstract: Methods of treating a subject having, or at risk of having, a myeloproliferative disorder are provided according to embodiments of the present invention which include administering a therapeutically effective amount of an arachidonate 5-lipoxygenase (5-LO) inhibitor to the subject. Combinations of therapeutic agents are administered according to embodiments of the present invention. In some embodiments, two or more 5-LO inhibitors are administered to a subject to treat a myeloproliferative disorder. In further embodiments, at least one 5-LO inhibitor and at least one additional therapeutic agent are administered to a subject to treat a myeloproliferative disorder. Methods of inhibiting leukemia stem cells are provided according to embodiments of the present invention which include contacting leukemia stem cells with an effective amount of an arachidonate 5-lipoxygenase inhibitor.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: March 11, 2014
    Assignee: The Jackson Laboratory
    Inventor: Shaoguang Li
  • Patent number: 8664273
    Abstract: The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: March 4, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Lindsay McNair, John McHutchison
  • Patent number: 8664247
    Abstract: The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: March 4, 2014
    Assignees: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Jan Scicinski, Bryan T. Oronsky, Robert Wardle, Louis Cannizzo, Nicholas A. Straessler
  • Publication number: 20140044658
    Abstract: This invention relates to the field of topical treatments for infections such as nail infections, particularly fungal infections of the nail commonly referred to as onychomycosis. Particularly, the invention relates to novel compositions containing peroxide for the treatment of such nail infections and other infections.
    Type: Application
    Filed: October 11, 2013
    Publication date: February 13, 2014
    Applicant: Thompson Cooper Laboratories, LLC
    Inventors: Eugene R. Cooper, Evan R. Thompson, Elliot R. Thompson
  • Publication number: 20140030367
    Abstract: A keratolytic emollient, which includes urea, mineral oil, and paraffin wax.
    Type: Application
    Filed: July 15, 2013
    Publication date: January 30, 2014
    Applicant: Prugen IP Holdings, Inc.
    Inventor: Bhiku G. Patel
  • Publication number: 20140018432
    Abstract: Method of single step electrochemical generation of chlorinated urea, chlorinated dimethylurea and other chlorourea derivatives is disclosed. The chlorinated species are generated in situ and upon demand and can be used for microbial control in industrial water treatment.
    Type: Application
    Filed: June 5, 2013
    Publication date: January 16, 2014
    Inventor: Davit E. Sharoyan
  • Patent number: 8603500
    Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: December 10, 2013
    Assignee: BIND Therapeutics, Inc.
    Inventors: Stephen E. Zale, Mir Mukkaram Ali
  • Patent number: 8603499
    Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: December 10, 2013
    Assignee: BIND Therapeutics, Inc.
    Inventors: Stephen E. Zale, Mir Mukkaram Ali
  • Patent number: 8603501
    Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: December 10, 2013
    Assignee: BIND Therapeutics, Inc.
    Inventors: Stephen E. Zale, Mir Mukkaram Ali
  • Patent number: 8591872
    Abstract: A process for reducing curl and/or frizziness of hair comprising: (a) providing a composition for reducing curl and/or frizziness of hair, said composition comprising, in a cosmetically acceptable carrier: (i) at least one non-hydroxide base; (ii) at least one protein denaturant different from (a)(i); (iii) at least one alkoxysilane comprising at least one solubilizing functional group; and (iv) optionally, at least one fatty substance; (b) contacting the hair with the composition in (a) to form treated hair; (c) optionally, rinsing the composition in (a) from the treated hair; (d) optionally, contacting the treated hair with a conditioning agent; (e) smoothing the treated hair using a combination of heat and means for physically smoothing hair to form smoothed hair; (f) optionally, shampooing the smoothed hair; and (g) rinsing the smoothed hair.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: November 26, 2013
    Assignee: L'Oreal
    Inventors: Jim Singer, Christine Shin, Sudarat Infahseng, Xiang Zhu, Clarissa Nogueira
  • Publication number: 20130225456
    Abstract: Composition and method for treating and/or preventing biological contamination using a biocide composition comprising at least one quaternary ammonium compound and urea. The method includes drying urea, and thereafter combining at least one quaternary ammonium compound and urea and may produce a potent biocide composition that is stable and able to chemically treat biological contamination in a variety of difficult to reach locations. Uses of the composition are also described.
    Type: Application
    Filed: November 30, 2012
    Publication date: August 29, 2013
    Applicant: UNITED PROMOTIONS, INC.
    Inventor: UNITED PROMOTIONS, INC.
  • Patent number: 8513302
    Abstract: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: August 20, 2013
    Assignee: The Regents of the University of California
    Inventors: Bruce D. Hammock, Takaho Watanabe, Seung-Jin Ma, Susan E. Bennett, Judith S. Stern, Christophe Morisseau, In-Hae Kim
  • Publication number: 20130202667
    Abstract: The present invention relates to hydrogel particles coated with lipid, which are made from dispersing hydrogel particles in an organic solvent in which lipids are dissolved, and to a method for manufacturing same. Unlike the existing method for manufacturing hydrogel core vesicles, the present invention can effectively manufacture same by using an emulsification method, without involving the steps of chemical treatment of the surface of hydrogels or dilution, thereby facilitating mass production and preventing the decrease of drug encapsulation efficiency.
    Type: Application
    Filed: October 12, 2011
    Publication date: August 8, 2013
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Eun Jung An, Do Hoon Kim, Hyung Jun Lim, Jong Won Shim, Choon Bok Jeong, Lee Kyoung Kwon, Jun Oh Kim
  • Publication number: 20130178532
    Abstract: The invention provides a process for manufacturing biocidal compositions containing bromourea derivatives, including the reaction of salts or adducts of the urea derivatives with an oxidizer.
    Type: Application
    Filed: September 19, 2011
    Publication date: July 11, 2013
    Applicant: BROMINE COMPOUNDS LTD.
    Inventors: Shomo Antebi, David Feldman
  • Patent number: 8470887
    Abstract: Provided, among other things, is a delivery module for a non-greasy, water-based urea composition comprising: an aerosol delivery device; within the aerosol delivery device, the urea composition comprising 20% or more urea by weight, non-greasy lipophilic component(s), and a frothing agent, the urea composition having a viscosity low enough to support aerosol delivery, and the urea composition effective to form a foam upon propellant-driven aerosol delivery; and within the aerosol delivery device, a propellant.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: June 25, 2013
    Assignee: Quinnova Pharamaceuticals, Inc.
    Inventor: Mats Silvander
  • Patent number: 8465725
    Abstract: A manufacturing process for the preparation of radiolabeled compounds of formula (I) includes reacting compounds of formula (II) with a source of radionuclide of a halogen in the presence of an oxidant under acidic condition, wherein: *I is 123I, 124I, 125I or 131I; R is lower alkyl, optionally substituted with one or more fluorine atoms; Q is C(O), O, NR?, S, S(O)2, C(O)2, (CH2)p; Y is C(O), O, NR?, S, S(O)2, C(O)2, (CH2)p; R? is H, C(O), S(O)2, C(O)2; Z is H, C1-C4 alkyl, benzyl, substituted benzyl or trialkylsilyl; m is 0, 1, 2, 3, 4 or 5; n is 0, 1, 2, 3, 4, 5 or 6; and p is 0, 1, 2, 3, 4, 5 or 6.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: June 18, 2013
    Assignee: Molecular Insight Pharmaceuticlas, Inc.
    Inventors: John W. Babich, Craig Zimmerman, Kevin P. Maresca
  • Publication number: 20130137773
    Abstract: Stabilized cationic ammonium compounds are described. The compounds are stabilized with pyridine-based chelators and/or heteroketo-based chelators that impede the generation of nitrogen comprising groups from the cationic ammonium compounds.
    Type: Application
    Filed: November 6, 2012
    Publication date: May 30, 2013
    Applicant: CONOPCO, INC., D/B/A UNILEVER
    Inventors: Van AU, Stephen Alan MADISON
  • Patent number: 8450378
    Abstract: This invention provides a method of inactivating human noroviruses and other acid stable viruses. The method includes the step of contacting the virus with a virucidally-enhanced alcoholic composition that includes an alcohol, and an enhancer selected from cationic oligomers and polymers, chaotropic agents, and mixtures thereof.
    Type: Grant
    Filed: August 9, 2008
    Date of Patent: May 28, 2013
    Assignee: GOJO Industries, Inc.
    Inventors: Marcia Snyder, David R. Macinga, James W. Arbogast
  • Publication number: 20130123203
    Abstract: Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder.
    Type: Application
    Filed: October 31, 2012
    Publication date: May 16, 2013
    Inventors: Paul Talalay, Andrew W. Zimmerman, Kirby D. Smith